Revolutionising the management of viral respiratory tract infections
Breathing new life into at-risk patients by transforming the prevention and treatment of viral respiratory infections
About us
Pneumagen is a clinical-stage biotech company developing Neumifil, its lead product, as an intranasal drug for the prophylaxis and treatment of a broad range of viral respiratory tract infections (RTIs).
Our mission is to develop truly innovative, life-saving, broad-spectrum antiviral therapies for the prevention of infection in at-risk patients, vulnerable to a broad range of respiratory tract infections.
Our lead product
Neumifil is a novel, engineered multivalent Carbohydrate Binding Module (mCBM), which is being developed as a broad-spectrum product for the prevention of viral respiratory infections including Influenza Virus, Respiratory Syncytial Virus, Human Rhinovirus, and Coronavirus Infections including SARS-CoV-2.
Neumifil was evaluated in a Phase 2 Influenza Human Challenge Study where participants were challenged with influenza virus following administration with Neumifil. Neumifil demonstrated a clinically significant reduction in the incidence of symptomatic influenza infection and in the severity of symptoms, which achieved statistical significance, compared to placebo. Neumifil was well tolerated with no new emergent adverse events or safety signals from the study compared to the first in human study.
Based on these positive clinical results, Pneumagen is planning to advance Neumifil into further clinical studies. This will include the evaluation of Neumifil’s ability to reduce the incidence of viral induced exacerbations in patients with Chronic Obstructive Pulmonary Disease (COPD).
Market opportunity
Respiratory viral infections are a major cause of exacerbations in patients with a range of respiratory diseases including, COPD, bronchiectasis and asthma. These exacerbations can accelerate the decline in lung function and lead to greater morbidity and mortality rates as well as significantly higher healthcare costs.
As a result, there is a significant medical need for the treatment of virally induced pulmonary exacerbations in patients with underlying respiratory diseases.
Currently, there are no treatments approved specifically to prevent infective exacerbations of chronic lung diseases. Without targeted treatment of the disease, therapy can be ineffective, and the exacerbations can have a negative impact on the quality of life of patients, accelerate disease progression and result in increased hospital admissions.
